Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 8

1.

Engineering cell-based therapies to interface robustly with host physiology.

Schwarz KA, Leonard JN.

Adv Drug Deliv Rev. 2016 Oct 1;105(Pt A):55-65. doi: 10.1016/j.addr.2016.05.019. Epub 2016 Jun 3. Review.

PMID:
27266446
2.

Assessing T-cell responses in anticancer immunotherapy: Dendritic cells or myeloid-derived suppressor cells?

Escors D, Liechtenstein T, Perez-Janices N, Schwarze J, Dufait I, Goyvaerts C, Lanna A, Arce F, Blanco-Luquin I, Kochan G, Guerrero-Setas D, Breckpot K.

Oncoimmunology. 2013 Oct 1;2(10):e26148. Epub 2013 Sep 12. Review.

3.

Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells.

Maher J.

ISRN Oncol. 2012;2012:278093. doi: 10.5402/2012/278093. Epub 2012 Dec 9.

4.

Targeting lentiviral vectors for cancer immunotherapy.

Arce F, Breckpot K, Collins M, Escors D.

Curr Cancer Ther Rev. 2011 Nov;7(4):248-260.

5.

Biology by design: from top to bottom and back.

Fritz BR, Timmerman LE, Daringer NM, Leonard JN, Jewett MC.

J Biomed Biotechnol. 2010;2010:232016. doi: 10.1155/2010/232016. Epub 2010 Nov 2. Review.

6.

Lentiviral vectors in gene therapy: their current status and future potential.

Escors D, Breckpot K.

Arch Immunol Ther Exp (Warsz). 2010 Apr;58(2):107-19. doi: 10.1007/s00005-010-0063-4. Epub 2010 Feb 9. Review.

7.

Dendritic cells for active anti-cancer immunotherapy: targeting activation pathways through genetic modification.

Breckpot K, Escors D.

Endocr Metab Immune Disord Drug Targets. 2009 Dec;9(4):328-43. Review.

8.

Characterization of murine dendritic cell line JAWS II and primary bone marrow-derived dendritic cells in Chlamydia muridarum antigen presentation and induction of protective immunity.

Jiang X, Shen C, Rey-Ladino J, Yu H, Brunham RC.

Infect Immun. 2008 Jun;76(6):2392-401. doi: 10.1128/IAI.01584-07. Epub 2008 Mar 24.

Supplemental Content

Support Center